

Improving the Design of Clinical Trials in T1D: Analysis of Data from the Trial Outcome Markers Initiative (TOMI) Collaboration

With presentations from JDRF, TrialNet and the TOMI-T1D Collaboration

The Trial Outcome Marker Initiative brings together data from many contributors in the field comprising more than 10,000 individuals with new onset T1D including 2900 from 21 different clinical trials. Analysis of C-peptide, HbA1c and as well as composite outcomes will be discussed which has provided significant insights into designing clinical trials in Stage 3 T1D.

You can register [here](#) and view the full agenda [here](#).



**May 24 | 2 PM CET
Room 109**



**10,000+
Individuals**



**21 Different
Clinical Trials**



**C-peptide,
HbA1c Analysis**



**Designing Trials
in Stage 3 T1D**

Improving the design of clinical trials in T1D

Analysis of data from the Trial Outcome Markers Initiative (TOMI) collaboration

*With presentations from JDRF,
TrialNet and the TOMI-T1D
Collaboration*



T1D

TYPE 1 DIABETES
CONSORTIUM

CRITICAL PATH INSTITUTE

c-path.org/t1d



TOMI-T1D

TRIAL OUTCOME MARKERS
INITIATIVE IN TYPE 1 DIABETES

CRITICAL PATH INSTITUTE

c-path.org/tomi-t1d

